Evidence map›Paper›PMID 40974303›Full record

ArticleBiochemistry2025

Biased Agonists of the Type 1 Angiotensin II Receptor Promote Distinct Subcellular β-Arrestin Conformations.

Anand Chundi, Uyen Pham, Srikrishna Darbha, Sudarshan Rajagopal

Abstract read
In one paragraph

Article in Biochemistry, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors.

Anand ChundiDepartment of Medicine, Duke University Medical Center, Durham, North Carolina 27710, United States.ORCID 0000-0001-8148-7479
Uyen PhamDepartment of Biochemistry, Duke University, Durham, North Carolina 27710, United States.
Srikrishna DarbhaTrinity College, Duke University, Durham, North Carolina 27710, United States.
Sudarshan RajagopalDepartment of Medicine, Duke University Medical Center, Durham, North Carolina 27710, United States.ORCID 0000-0002-3443-5040

Funding

Biasing CXCR3 Signaling to Modulate the Inflammatory ResponseR01GM122798 · NIGMS · DUKE UNIVERSITY · PI RAJAGOPAL, SUDARSHAN · 2017 to 2025
$3.2M
A Novel high resolution MS platform for high-throughput screening of G protein-coupled receptorsR01GM149650 · NIGMS · BATTELLE PACIFIC NORTHWEST LABORATORIES · PI Jon Jacobs, Sudarshan Rajagopal · 2023 to 2026
$1.6M
NIGMS NIH HHS R01 GM122798NIGMS NIH HHS R01 GM149650
6 · The paper itself

Abstract

G protein-coupled receptors (GPCRs) are central to cellular signaling and therapeutic targeting. Ligands that activate the same GPCR can selectively activate some signaling pathways over others, a phenomenon termed biased agonism. Additionally, the same ligand and receptor complex can elicit distinct signaling profiles in different subcellular locations (location bias). Here, we examine how various biased agonists influence the recruitment of β-arrestins 1 and 2 induced by the angiotensin II type 1 receptor at the receptor, plasma membrane, and early endosomes. We also assessed β-arrestin conformational states at the receptor and plasma membrane. Using split luciferase and BRET assays, we demonstrate that angiotensin II, its G protein-biased analogs (TRV055, TRV056), and its β-arrestin-biased analogs (TRV023, TRV026, TRV027, TRV034) functionally stratify into two clusters. G protein-biased agonists and AngII predominantly favor a receptor-β-arrestin core complex conformation driven by engagement of the β-arrestin finger loop with the receptor core. In contrast, β-arrestin-biased agonists promote a tail complex configuration of receptor-associated β-arrestins. However, the conformations of β-arrestins monitored at the plasma membrane were found to be unaffected by ligand bias. Furthermore, balanced and G protein-biased ligands induced higher levels of ERK activation in subcellular locations (nucleus, cytosol, and early endosomes) over the β-arrestin-biased ligands, but equal ERK activity at the plasma membrane. Our findings highlight the interplay between ligand and location biases in dictating GPCR signaling, revealing new insights into the molecular mechanisms driving selective signal propagation.

Indexed as

beta-Arrestin 1beta-Arrestin 2beta-ArrestinsReceptor, Angiotensin, Type 1Angiotensin IICell MembraneEndosomesHEK293 CellsHumansProtein ConformationSignal TransductionAngiotensin IIbeta-Arrestin 1beta-Arrestin 2beta-ArrestinsReceptor, Angiotensin, Type 1

Identifiers

PMID40974303
PMCPMC13267248

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.